|
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer Clinical research trials and Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer. Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer clinical trial. Test subjects typically obtain the finest healthcare available for their Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer  Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
For Condition: stage 4 breast cancer,recurrent breast cancer
Status: Recruiting
Sponsor(s): Swiss Institute for Applied Cancer Research ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to determine the effectiveness of combining capecitabine and paclitaxel in treating patients who have metastatic breast cancer.
Details: OBJECTIVES: - Determine the maximum tolerated dose (MTD) of capecitabine when combined with paclitaxel in patients with metastatic adenocarcinoma of the breast. - Determine the clinical efficacy of the dose immediately preceding the MTD identified in phase I, in terms of response rate, time to treatment failure, time to disease progression, and overall survival, in these patients. - Determine the toxicity of this regimen in these patients. - Determine a well-tolerated drug combination for these patients. OUTLINE: This is a dose-escalation, multicenter study of capecitabine. Patients receive oral capecitabine twice daily on days 1-14 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 or more of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at the dose level immediately preceding the MTD. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for phase I and 15-46 patients will be accrued for phase II of this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/64 Years
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed metastatic adenocarcinoma of the breast - Patients in phase I: - Evaluable disease - Patients in phase II: - Bidimensionally measurable disease - Bone metastases are not considered measurable - No known or clinically suspected CNS metastases - Hormone receptor status: - Not specified PATIENT CHARACTERISTICS: Age: - 18 to 64 Sex: - Not specified Menopausal status: - Not specified Performance status: - WHO 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - WBC greater than 3,500/mm^3 - Platelet count greater than 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin no greater than 1.5 times upper limit of normal (ULN) - AST/ALT no greater than 2 times ULN (3 times ULN if liver metastases present) Renal: - Patients in phase I: - Creatinine clearance at least 50 mL/min - Patients in phase I or II: - Creatinine no greater than 1.5 times ULN Cardiovascular: - No grade 2 or greater atrioventricular block Other: - No cognitive impairment or severe psychiatric disorder - No greater than grade 2 preexisting peripheral neuropathy - No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer - Able to tolerate steroid premedication PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - More than 6 months since prior adjuvant chemotherapy - At least 1 year since prior continuous infusion of fluorouracil or capecitabine - At least 1 year since prior taxane administered once every 3 weeks - No prior taxane or capecitabine administered weekly - No more than 1 prior chemotherapy regimen for metastatic or locally advanced breast cancer - No other concurrent chemotherapy Endocrine therapy: - Prior hormonal treatment for metastatic breast cancer allowed - No concurrent continuous glucocorticosteroids - No concurrent systemic endocrine treatment for breast cancer Radiotherapy: - No concurrent radiotherapy to indicator lesion or more than 30% of bone marrow Surgery: - Not specified Other: - No other concurrent anticancer treatment - No concurrent immunosuppressive drugs - Concurrent bisphosphonates allowed if indicator lesion is non-bone - Able to tolerate steroid premedication
Total Enrollment:
Location and Contact Information:
Overall Study Official:
StefanAebi, Study Chair, Inselspital, Bern
Inselspital, Bern *Recruiting*
Bern, , CH-3010
Switzerland
Recruiting Stefan Aebi 41-031-632-41-14
UniversitaetsSpital *Recruiting*
Zurich, , CH-8091
Switzerland
Recruiting Bernhard Pestalozzi 41-31-255-2214
Additional Information:
Study ID Numbers: CDR0000069236; EU-20135,SWS-SAKK-26/00
Study Start Date:
Record last reviewed: March 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00031876
Other Stage 4 Breast Cancer Studies:
1. CP-724,714 in Treating Patients With Metastatic Breast Cancer
2. Radioimmunotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast Cancer
3. Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer
4. Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
5. Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Related Studies:
Other stage 4 breast cancer Clinical Trials
Other Clinical Trials
Other Bern Clinical Trials
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
|
|
|
|
|
|
|
|
